A Population-Based Registry Analysis on Hospitalized COVID-19 Patients with Previous Cardiovascular Disease: Clinical Profile, Treatment, and Predictors of Death.
J Cardiovasc Dev Dis
; 8(12)2021 Nov 29.
Article
in English
| MEDLINE | ID: covidwho-1542593
ABSTRACT
A high percentage of patients with COVID-19 (coronavirus disease 2019) have previous cardiovascular disease (CVD). The findings presented here came from an epidemiological population-based registry study (real-world data) that enrolled all in-hospital COVID-19 patients with previous CVD from 1 March to 31 May 2020. Death, other comorbidities, hospital stay variables, ventilation type, and main clinical outcomes were evaluated. In Castile and Leon, 35.83% of the 7307 in-hospital COVID-19 patients who participated in this study had previous CVD, particularly arrhythmias (48.97%), cerebrovascular disease (25.02%), ischemic heart disease (22.8%), and chronic heart failure (20.82%). Of the patients, 21.36% were men and more than 90% were over 65 years of age, and the mortality rate achieved 32.93%. The most used medicines were antibiotics (91.41%), antimalarials (73.3%), steroids (46.64%), and antivirals (43.16%). The main predictors of death were age over 65 years (OR 5), ventilation needs (OR 2.81), treatment with anti-SIRS (systemic inflammatory response syndrome) medicines (OR 1.97), antivirals (OR 1.74) or steroids (OR 1.68), SIRS (OR 5.75), SARS (severe acute respiratory syndrome) (OR 2.44), or AKI (acute kidney injury) (OR 1.63) occurrence. Chronic heart failure and cerebrovascular disease were associated with a worse clinical course of COVID-19, especially in men older than 65 years with diabetes who developed SIRS, SARS, or AKI.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Jcdd8120167
Similar
MEDLINE
...
LILACS
LIS